Fig. 2. Comparison of the mean fluorescence intensities (MFIs) of donor HLA-specific antibodies (DSAs) present in RTX+/DSA+ and RTX−/DSA+ sera. (A) The MFI values of all DSAs in the RTX+/DSA+ and RTX−/DSA+ groups at 1, 2, and 3 mg/mL pronase were plotted according to the B-cell flow cytometry crossmatch (FCXM) results (positive or negative). For cases with two DSAs, the MFI sum of both DSAs was used. (B) The FCXM-negative cases represented in (A) were divided into the RTX+/DSA+ and RTX−/DSA+ groups and subdivided according to 1, 2, and 3 mg/mL pronase treatment (P1, P2, and P3, respectively). The horizontal lines and error bars represent the median and interquartile range of each column, respectively.
Abbreviations: RTX, rituximab; XM, crossmatches; ns, not significant.

Ann Lab Med 2024;44:545~552 https://doi.org/10.3343/alm.2024.0132